Anti-tumor agents

• US 20050272703A1
• Filed: 05/17/2005
• Published: 12/08/2005
• Est. Priority Date: 05/25/1999
• Status: Active Grant

• Current Assignee: DARA Biosciences Incorporated (Barings LLC (Private Equity))
• Original Assignee: Point Therapeutics, Inc. (Barings LLC (Private Equity))
• Inventors: Miller, Glenn, Wallner, Barbara
• Granted Patent: US 7,259,138 B2
• Time in Patent Office: Days
• US Class Current: 514/64
• CPC Class Codes: A61K 31/69 Boron compounds
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.

Claims

1. A method for treating a subject having a condition characterized by an abnormal mammalian cell proliferation, comprising:

administering to a subject in need of such treatment, an agent in an amount effective to inhibit the proliferation, wherein the agent is a compound of Formula I.

2. The method of claim 1, wherein the abnormal mammalian cell proliferation is manifested as a tumor.

3. The method of claim 1, wherein the condition is further characterized by the presence of reactive stromal fibroblasts.

4. The method of claim 1, wherein the abnormal mammalian cell proliferation is in epithelial cells.

5. The method of claim 4, wherein the abnormal mammalian cell proliferation is selected from the group consisting of a carcinoma, a sarcoma, and a melanoma.

6. The method of claim 1, wherein the condition is a metastasis of epithelial origin.

7. The method of claim 1, wherein the condition is selected from the group consisting of breast cancer, colorectal cancer, ovarian cancer prostate cancer, pancreatic cancer, kidney cancer, lung cancer, melanoma and fibrosarcoma.

8. The method of claim 1, wherein the condition is selected from the group consisting of bone and connective tissue sarcomas.

9. The method of claim 1, wherein the agent is administered locally.

10. The method of claim 1, wherein the agent is administered systemically.

11. The method of claim 1, wherein the subject is otherwise free of symptoms calling for hemopoietic stimulation.

12. The method of claim 1, wherein the agent is administered in combination with surgery to remove an abnormal proliferative cell mass.

13. The method of claim 1, wherein the agent is administered to a patient who has had surgery to remove an abnormal proliferative cell mass.

14. The method of claim 1, wherein the agent is administered in combination with an anti-cancer compound.

15. The method of claim 1, wherein the agent is targeted to a tumor.

16. The method of claim 1, wherein the subject has normal hemopoietic activity.

17. The method of claim 1, wherein the subject is HIV negative.

18. The method of claim 1, wherein the agent is Val-boro-Pro.

19. A method for inhibiting angiogenesis in a subject having a condition characterized by abnormal mammalian cell proliferation comprising:

administering to a subject in need of such treatment, an agent in an amount effective to inhibit angiogenesis in an abnormal proliferative cell mass, wherein the agent is a compound of Formula I.

20. The method of claim 19, wherein the abnormal mammalian cell proliferation is manifested as a tumor.

21-37. -37. (canceled)